Our way to help you developing cancer vaccines
Destruction of tumor vasculature integrity by vaccination represents one of the most attractive cancer immunotherapy approaches due to its ability to prevent growth of solid cancers. SANTAVAC ™ – the first antigen composition based on endothelial cell heterogeneity – allows targeting of the tumor vasculature with a high predicted efficacy. These data suggest that use of SANTAVAC ™ as a universal antigenic composition may spur vaccine development activities resulting in a set of therapeutic or prophylactic vaccines against different types of solid cancers. The large-scale implementation of SANTAVAC ™ as antigens suitable for the treatment and prevention of diverse types of cancers is a current aim of BioBohemia.